Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine

• Egile Nagusiak: Francesca Schiano di Cola (Egilea), Marco Bolchini (Egilea), Salvatore Caratozzolo (Egilea), Giulia Ceccardi (Egilea), Matteo Cortinovis (Egilea), Paolo Liberini (Egilea), Renata Rao (Egilea), Alessandro Padovani (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2023-02-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: The aim of the present study was to assess the migraine outcome, in particular migraine disability, in chronic (CM) and high frequency episodic migraine (HFEM) patients in treatment with galcanezumab. Methods: The present study was conducted at the Headache Centre of Spedali Civili of Br...